Thu, December 12, 2024
Wed, December 11, 2024
[ Wed, Dec 11th 2024 ]: ProPublica
An Open Letter to Elon Musk
[ Wed, Dec 11th 2024 ]: techUK
Nations and Regions 2024 round-up
[ Wed, Dec 11th 2024 ]: Mercury News
California Politics
[ Wed, Dec 11th 2024 ]: The Nation
Remembering Fred Harris
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ]: spectator.com.au
The return of politics

Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump

  Copy link into your clipboard //politics-government.news-articles.net/content/ .. -drug-affordability-are-focuses-under-trump.html
  Print publication without navigation Published in Politics and Government on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump administration.

The article from MSN discusses comments made by David Ricks, the CEO of Eli Lilly, regarding the pharmaceutical industry's priorities under a potential second term of former President Donald Trump. Ricks highlighted that the industry is focused on tax and regulation reform, as well as addressing drug affordability. He noted that while Trump's previous administration had been supportive of the industry through tax cuts and deregulation, there were also pressures to lower drug prices. Ricks expressed hope for a balanced approach that would encourage innovation while making medications more accessible and affordable to patients. He also mentioned the importance of maintaining a dialogue with policymakers to ensure that any reforms would not stifle the development of new treatments.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/politics/government/lilly-ceo-says-tax-and-regulation-reform-drug-affordability-are-focuses-under-trump/ar-AA1vCOZf ]